Oct 15 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* CEO responds to Sen. McCaskill in a letter dated October 14, 2015
* CEO - Valeant implemented increases in list prices to ensure that prices
reflected value of drugs to hospitals and patients
* CEO -in Q2 2015,reported overall revenue of $4.92 billion; reported revenues
from Nitropress of $126 million, from Isuprel of $121 million
* CEO says "revenues from Nitropress and Isuprel represent a relatively small
portiion of our overall revenue and profitability"
* CEO - co's list price for Nitropress is $880.88/vial,$1472.25/vial for
Isuprel in a 1ml package,$1709.11/vial for 5 ml package
* CEO -"there is a misperception in the media" that co's revenue growth for
existing products has been driven primarily by price
* CEO - average selling price of products co owned was $316.86 for Q3 2015
versus $280.82 for Q3 2014,representing 13 percent increase
* CEO - Nitropress, Isuprel continue to be maufactured by Hospira Inc (N:HSP) under
contracts that existed when they were acquired by co
* CEO - "Valeant has not implemented material changes to Nitropress or Isuprel
since the products were acquired from Marathon"
* CEO-pricing consultant confirms there was room to raise price of Nitropress,Isuprel without depleting funds available to hospitals from payers
* Further company coverage VRX.TO